AU2014220735B2 - Vortioxetine manufacturing process - Google Patents

Vortioxetine manufacturing process Download PDF

Info

Publication number
AU2014220735B2
AU2014220735B2 AU2014220735A AU2014220735A AU2014220735B2 AU 2014220735 B2 AU2014220735 B2 AU 2014220735B2 AU 2014220735 A AU2014220735 A AU 2014220735A AU 2014220735 A AU2014220735 A AU 2014220735A AU 2014220735 B2 AU2014220735 B2 AU 2014220735B2
Authority
AU
Australia
Prior art keywords
compound
formula
piperazine
process according
equivalents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014220735A
Other languages
English (en)
Other versions
AU2014220735A1 (en
Inventor
Kim Lasse Christensen
Thomas Ruhland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2014220735A1 publication Critical patent/AU2014220735A1/en
Application granted granted Critical
Publication of AU2014220735B2 publication Critical patent/AU2014220735B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02Iron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
AU2014220735A 2013-02-22 2014-02-20 Vortioxetine manufacturing process Active AU2014220735B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361767883P 2013-02-22 2013-02-22
DKPA201300104 2013-02-22
DKPA201300104 2013-02-22
PCT/EP2014/053313 WO2014128207A1 (en) 2013-02-22 2014-02-20 Vortioxetine manufacturing process

Publications (2)

Publication Number Publication Date
AU2014220735A1 AU2014220735A1 (en) 2015-08-20
AU2014220735B2 true AU2014220735B2 (en) 2017-06-22

Family

ID=59215387

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014220735A Active AU2014220735B2 (en) 2013-02-22 2014-02-20 Vortioxetine manufacturing process

Country Status (37)

Country Link
US (1) US9353073B2 (enExample)
EP (1) EP2958903B1 (enExample)
JP (1) JP6464098B2 (enExample)
KR (1) KR102230628B1 (enExample)
CN (1) CN104995181B (enExample)
AP (1) AP2015008640A0 (enExample)
AU (1) AU2014220735B2 (enExample)
BR (1) BR112015019268B1 (enExample)
CA (1) CA2901821A1 (enExample)
CL (1) CL2015002309A1 (enExample)
CR (1) CR20150423A (enExample)
CY (1) CY1118883T1 (enExample)
DK (1) DK2958903T3 (enExample)
DO (1) DOP2015000187A (enExample)
EA (1) EA027756B1 (enExample)
ES (1) ES2625380T3 (enExample)
GE (1) GEP201706749B (enExample)
HR (1) HRP20170607T1 (enExample)
IL (1) IL240501B (enExample)
LT (1) LT2958903T (enExample)
MA (1) MA38338B1 (enExample)
ME (1) ME02671B (enExample)
MX (1) MX362355B (enExample)
MY (1) MY172337A (enExample)
PE (1) PE20151589A1 (enExample)
PH (1) PH12015501807B1 (enExample)
PL (1) PL2958903T3 (enExample)
PT (1) PT2958903T (enExample)
RS (1) RS55932B1 (enExample)
RU (1) RU2652265C2 (enExample)
SG (1) SG11201506651SA (enExample)
SI (1) SI2958903T1 (enExample)
SM (1) SMT201700238T1 (enExample)
TN (1) TN2015000335A1 (enExample)
UA (1) UA116236C2 (enExample)
WO (1) WO2014128207A1 (enExample)
ZA (1) ZA201506050B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354133B (es) 2010-08-18 2018-02-14 Samumed Llc Dicetonas e hidroxicetonas como activadores de la trayectoria de señalizacion de catenina.
MY176004A (en) 2013-02-22 2020-07-21 Samumed Llc Gamma-diketones as wnt/beta-catenin signaling pathway activators
EP3206686B1 (en) 2014-08-20 2019-10-09 Samumed, LLC Gamma-diketones for treatment and prevention of aging skin and wrinkles
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN106279065A (zh) * 2015-05-12 2017-01-04 北京深蓝海生物医药科技有限公司 一种氢溴酸沃替西汀的精制转晶方法
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
ES2819831T3 (es) * 2016-02-08 2021-04-19 H Lundbeck As Síntesis de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]piperazina
US9820984B1 (en) 2016-07-01 2017-11-21 H. Lundbeck A/S Dosing regimens for fast onset of antidepressant effect
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN109912538B (zh) * 2019-01-22 2021-03-12 安徽赛乐普制药有限公司 一种抗抑郁药沃替西汀的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029232A1 (en) * 2001-10-04 2003-04-10 H. Lundbeck A/S Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161966A0 (en) * 2001-12-20 2005-11-20 Lundbeck & Co As H Aryloxyphenyl and arylsulfanylphenyl
US8722684B2 (en) * 2006-06-16 2014-05-13 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029232A1 (en) * 2001-10-04 2003-04-10 H. Lundbeck A/S Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Also Published As

Publication number Publication date
US9353073B2 (en) 2016-05-31
RU2652265C2 (ru) 2018-04-27
PL2958903T3 (pl) 2017-08-31
SI2958903T1 (sl) 2017-09-29
UA116236C2 (uk) 2018-02-26
MA38338A1 (fr) 2016-09-30
TN2015000335A1 (en) 2017-01-03
CA2901821A1 (en) 2014-08-28
CY1118883T1 (el) 2018-01-10
PE20151589A1 (es) 2015-12-03
HK1216098A1 (en) 2016-10-14
PH12015501807B1 (en) 2019-05-31
SG11201506651SA (en) 2015-09-29
JP6464098B2 (ja) 2019-02-06
MX362355B (es) 2019-01-14
EA027756B1 (ru) 2017-08-31
AU2014220735A1 (en) 2015-08-20
CN104995181A (zh) 2015-10-21
WO2014128207A1 (en) 2014-08-28
RS55932B1 (sr) 2017-09-29
PT2958903T (pt) 2017-05-26
MX2015010656A (es) 2015-12-17
HRP20170607T1 (hr) 2017-06-30
IL240501B (en) 2018-08-30
AP2015008640A0 (en) 2015-08-31
MY172337A (en) 2019-11-21
LT2958903T (lt) 2017-08-25
EA201591349A1 (ru) 2015-12-30
ES2625380T3 (es) 2017-07-19
EP2958903B1 (en) 2017-04-12
RU2015134407A (ru) 2017-03-28
GEP201706749B (en) 2017-10-10
ZA201506050B (en) 2017-08-30
BR112015019268B1 (pt) 2023-01-10
BR112015019268A2 (pt) 2020-01-28
CN104995181B (zh) 2017-03-08
DK2958903T3 (en) 2017-05-15
PH12015501807A1 (en) 2015-11-09
IL240501A0 (en) 2015-09-24
DOP2015000187A (es) 2015-11-30
US20160009670A1 (en) 2016-01-14
CR20150423A (es) 2015-10-20
KR20150118146A (ko) 2015-10-21
ME02671B (me) 2017-06-20
JP2016509042A (ja) 2016-03-24
MA38338B1 (fr) 2018-10-31
EP2958903A1 (en) 2015-12-30
KR102230628B1 (ko) 2021-03-22
CL2015002309A1 (es) 2016-03-04
SMT201700238T1 (it) 2017-07-18

Similar Documents

Publication Publication Date Title
AU2014220735B2 (en) Vortioxetine manufacturing process
CN104011034B (zh) 用于生产1-[2-(2,4-二甲基-苯基硫烷基)-苯基]-哌嗪的方法
JP6451652B2 (ja) (r)−1,1,3−トリメチル−4−アミノインダンの製造方法
KR20220051168A (ko) 헤테로시클리덴아세트아미드 유도체의 제조 방법
CN105348220B (zh) 一种氢溴酸沃替西汀的合成方法
CN104628676A (zh) 一种Vortioxetine的制备方法
HK1216098B (en) Vortioxetine manufacturing process
OA17454A (en) Vortioxetine manufacturing process.
CN107011288B (zh) 一种阿立哌唑中间体1-(2,3-二氯苯基)哌嗪盐酸盐的制备方法
NZ710779A (en) Vortioxetine manufacturing process
NZ710779B2 (en) Vortioxetine manufacturing process
JP2025083072A (ja) ボルチオキセチンの製造方法
JP5439745B2 (ja) ハロゲノメチルペンタフルオロスルファニルベンゼン化合物及びその製造方法
CN103922996B (zh) 一种药物新型中间体及其制备方法
TW201825463A (zh) 用於製備1-(4-(2-((1-(3,4-二氟苯基)-1h-吡唑-3-基)甲氧基)乙基)哌-1-基)乙酮的方法和中間體
JP2011207844A (ja) ビベンゾイミダゾール化合物の製造方法
JP2022506577A (ja) D3ドーパミン受容体アゴニストを合成する方法
JP2007070300A (ja) 2,5−ジアミノ−1,4−ベンゾキノン及び2,5−ジアミノ−1,4−ベンゼンジオール、およびその塩の製造方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ PA201300104 22 FEB 2013 DK

FGA Letters patent sealed or granted (standard patent)